Published in Ann Surg on January 01, 2011
Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant (2012) 1.10
Liver transplantation for hepatocellular carcinoma. Liver Cancer (2013) 1.01
Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer (2014) 1.00
Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol (2011) 1.00
Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer (2012) 0.99
Hepatocellular carcinoma: A comprehensive review. World J Hepatol (2015) 0.98
The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size. World J Surg (2015) 0.96
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol (2015) 0.96
Hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.95
Hepatocellular carcinoma--resection or transplant? Nat Rev Gastroenterol Hepatol (2012) 0.92
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol (2013) 0.92
Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma. Curr Oncol (2013) 0.84
Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol (2013) 0.83
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol (2015) 0.82
Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol (2015) 0.81
Endothelial cells do not arise from tumor-initiating cells in human hepatocellular carcinoma. BMC Cancer (2013) 0.81
The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis. PLoS One (2012) 0.80
Primary liver transplantation vs liver resection followed by transplantation for transplantable hepatocellular carcinoma: Liver functional quality and tumor characteristics matter. World J Gastrointest Surg (2013) 0.80
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation (2014) 0.79
Liver transplantation for hepatocellular carcinoma: past, present and future. Middle East J Dig Dis (2013) 0.79
Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford) (2012) 0.79
In hepatocellular carcinomas, any proportion of poorly differentiated components is associated with poor prognosis after hepatectomy. World J Surg (2014) 0.79
Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol (2016) 0.78
Selection Criteria and Current Issues in Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer (2016) 0.78
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol (2017) 0.78
Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6. Clin Cancer Res (2015) 0.77
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol (2015) 0.77
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg (2017) 0.76
The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its success. Can J Gastroenterol Hepatol (2015) 0.76
Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol (2015) 0.76
From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. World J Hepatol (2015) 0.76
Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol (2016) 0.76
Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. J Hepatocell Carcinoma (2016) 0.75
Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr (2016) 0.75
LIVER TRANSPLANTATION FOR CARCINOMA HEPATOCELLULAR IN SÃO PAULO: 414 CASES BY THE MILAN/BRAZIL CRITERIA. Arq Bras Cir Dig (2017) 0.75
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. ISRN Hepatol (2014) 0.75
HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med (2016) 0.75
Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol (2016) 0.75
Prognosis in the early stages of hepatocellular carcinoma: Predicting outcomes and properly selecting patients for curative options. Can J Gastroenterol (2011) 0.75
Metabolic profiling of hepatitis B virus-related hepatocellular carcinoma with diverse differentiation grades. Oncol Lett (2017) 0.75
Twenty years of Milan criteria: how far do we go. Hepatobiliary Surg Nutr (2016) 0.75
Historical perspective on the importance of the Milan criteria. Hepatobiliary Surg Nutr (2016) 0.75
Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience. J Transplant (2016) 0.75
Liver transplantation: Toward a unified allocation system. Nat Rev Gastroenterol Hepatol (2011) 0.75
Imaging follow-up after liver transplantation. Br J Radiol (2016) 0.75
Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation. Int J Clin Oncol (2016) 0.75
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes. Transpl Int (2013) 2.62
A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg (2003) 2.48
Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg (2006) 2.37
Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg (2015) 2.36
Bile duct injuries associated with laparoscopic cholecystectomy: timing of repair and long-term outcomes. Arch Surg (2010) 2.26
Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery (2006) 2.24
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17
How should transection of the liver be performed?: a prospective randomized study in 100 consecutive patients: comparing four different transection strategies. Ann Surg (2005) 2.16
Thrombolytic protocol minimizes ischemic-type biliary complications in liver transplantation from donation after circulatory death donors. Liver Transpl (2015) 2.15
A prospective study of subclinical myocardial damage in endovascular versus open repair of infrarenal abdominal aortic aneurysms. J Vasc Surg (2005) 2.05
Loss of liver transplant surgeons into alternate career paths. Transpl Int (2014) 2.04
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol (2006) 2.02
Organ donor management in Canada: recommendations of the forum on Medical Management to Optimize Donor Organ Potential. CMAJ (2006) 1.73
Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant (2010) 1.59
Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation (2006) 1.59
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest (2003) 1.58
Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg (2005) 1.50
Pregnancy and sexual function in liver transplantation. J Hepatol (2008) 1.49
Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol (2005) 1.47
A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB (Oxford) (2012) 1.45
Versican 3'-untranslated region (3'-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J (2012) 1.44
Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology (2013) 1.41
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg (2006) 1.39
Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg (2005) 1.39
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38
ICAM-1 triggers liver regeneration through leukocyte recruitment and Kupffer cell-dependent release of TNF-alpha/IL-6 in mice. Gastroenterology (2003) 1.37
Pancreatic resection for metastatic renal cell carcinoma: presentation, treatment, and outcome. Ann Surg Oncol (2003) 1.35
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35
Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery (2002) 1.29
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28
In situ replication of immediate dendritic cell (DC) precursors contributes to conventional DC homeostasis in lymphoid tissue. J Immunol (2006) 1.24
Immunostimulatory conventional dendritic cells evolve into regulatory macrophage-like cells. Blood (2012) 1.23
A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg (2011) 1.23
GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis (2003) 1.19
Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19
Recurrent pyogenic cholangitis with hepatolithiasis--the role of surgical therapy in North America. J Gastrointest Surg (2007) 1.18
Characterization of mutant MUTYH proteins associated with familial colorectal cancer. Gastroenterology (2008) 1.18
Prognosis and results after resection of very large (>or=10 cm) hepatocellular carcinoma. J Gastrointest Surg (2007) 1.17
Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant (2012) 1.15
Live donor liver transplantation in high MELD score recipients. Ann Surg (2010) 1.14
Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol (2005) 1.13
A trajectory model for understanding and assessing health disparities in immigrant/refugee communities. J Immigr Minor Health (2011) 1.13
Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. J Hepatol (2003) 1.13
Synaptosome-associated protein of 25 kilodaltons modulates Kv2.1 voltage-dependent K(+) channels in neuroendocrine islet beta-cells through an interaction with the channel N terminus. Mol Endocrinol (2002) 1.13
An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol (2007) 1.11
Eight-Hour Continuous Normothermic Ex Vivo Kidney Perfusion Is a Safe Preservation Technique for Kidney Transplantation: A New Opportunity for the Storage, Assessment, and Repair of Kidney Grafts. Transplantation (2016) 1.10
The intrinsic renal compartment syndrome: new perspectives in kidney transplantation. Transplantation (2010) 1.10
Continuous Normothermic Ex Vivo Kidney Perfusion Improves Graft Function in Donation After Circulatory Death Pig Kidney Transplantation. Transplantation (2017) 1.08
Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One (2012) 1.07
Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl (2012) 1.06
Characterization of distinct conventional and plasmacytoid dendritic cell-committed precursors in murine bone marrow. J Immunol (2004) 1.05
Analysis and outcomes of right lobe hepatectomy in 101 consecutive living donors. Am J Transplant (2005) 1.04
Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol (2004) 1.03
Comparison of outcomes and costs between laparoscopic distal pancreatectomy and open resection at a single center. Surg Endosc (2011) 1.03
Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). AJR Am J Roentgenol (2015) 1.03
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res (2004) 1.02
Can genetic variations predict HCV treatment outcomes? J Hepatol (2008) 1.01
The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology (2009) 1.01